Suppression of F-18 fluorodeoxyglucose uptake in benign uterine leiomyomas with danazol

Madhavi Tripathi, Madhur Srivastava, Gunjun Garg, Abhinav Jaimini, Namita Singh, Maria D. Souza, Prabhjot Kaur, Rajnish Sharma, Anupam Mandal

Research output: Contribution to journalArticlepeer-review


A 40-year premenopausal woman was referred by her treating oncologist for F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to rule out disease recurrence or metastasis. She had completed therapy for Hodgkin lymphoma (Stage IIA) 1 year earlier. Post-therapy gallium-67 study showed no evidence of residual disease and the patient was on regular follow-up. The only abnormality detected on the FDG-PET/CT study was a focus of abnormal FDG accumulation in the pelvis, suprapubically. Fused PET-CT localized the uptake to the uterine myometrium in the fundal region posteriorly corresponding to mild inhomogeneity in attenuation with a bulky uterus on CT. MRI of the pelvis confirmed the presence of a uterine leiomyoma in the fundal region. The patient was put on danazol (200 mg twice daily for 14 days) and a repeat PET-CT of the pelvis was done after 14 days, which revealed complete disappearance of FDG uptake in the leiomyoma. This proved that F-18 FDG uptake in the leiomyoma was probably related to its vascularity.

Original languageEnglish (US)
Pages (from-to)452-455
Number of pages4
JournalClinical nuclear medicine
Issue number7
StatePublished - Jul 2009
Externally publishedYes


  • Danazol
  • F-18 FDG
  • Leiomyoma
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Suppression of F-18 fluorodeoxyglucose uptake in benign uterine leiomyomas with danazol'. Together they form a unique fingerprint.

Cite this